Novavax said the European Medicines Agency (EMA) recommended for approval its Covid-19 vaccine amid a rapid spread of the Omicron variant.

The EMA granted conditional marketing authorization to the company’s vaccine for people 18 years and older.

CMA is a fast-tracked authorization process and Novavax “must provide further data from ongoing or new studies within pre-defined deadlines to confirm that the benefits continue to outweigh the risks,” according to a press release from the EMA.